These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17685873)

  • 1. Nv-52: a novel thromboxane synthase inhibitor for the treatment of inflammatory bowel disease.
    Howes LG; James MJ; Florin T; Walker C
    Expert Opin Investig Drugs; 2007 Aug; 16(8):1255-66. PubMed ID: 17685873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ridogrel. R 68070.
    Drugs R D; 1999 Mar; 1(3):270-2. PubMed ID: 10566044
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase Ib single- and multiple-dose pharmacokinetic study of oral NV-52 in healthy volunteers.
    Howes LG; Howes JB; Huang JL; Walker C
    Drugs R D; 2008; 9(3):159-66. PubMed ID: 18457468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E 3040.
    Drugs R D; 1999 Mar; 1(3):256-7. PubMed ID: 10566039
    [No Abstract]   [Full Text] [Related]  

  • 5. Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer.
    Cathcart MC; Gately K; Cummins R; Kay E; O'Byrne KJ; Pidgeon GP
    Mol Cancer; 2011 Mar; 10():25. PubMed ID: 21388528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thromboxane A2 synthase inhibitors prevent production of infectious hepatitis C virus in mice with humanized livers.
    Abe Y; Aly HH; Hiraga N; Imamura M; Wakita T; Shimotohno K; Chayama K; Hijikata M
    Gastroenterology; 2013 Sep; 145(3):658-67.e11. PubMed ID: 23684750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thromboxane A Synthase: A New Target for the Treatment of Cardiovascular Diseases.
    Mesitskaya DF; Syrkin AL; Aksenova MG; Zhang Y; Zamyatnin AA; Kopylov PY
    Cardiovasc Hematol Agents Med Chem; 2018; 16(2):81-87. PubMed ID: 30039765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental non-steroidal anti-inflammatory drug-induced enteropathy in the rat: similarities to inflammatory bowel disease and effect of thromboxane synthetase inhibitors.
    Banerjee AK; Peters TJ
    Gut; 1990 Dec; 31(12):1358-64. PubMed ID: 1979954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro.
    Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
    Br J Pharmacol; 1993 Dec; 110(4):1600-6. PubMed ID: 8306107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers.
    Uematsu T; Kosuge K; Umemura K; Nakano M; Terakawa M; Nakashima M
    J Pharm Pharmacol; 1996 Apr; 48(4):380-5. PubMed ID: 8794987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboxane synthase immunohistochemistry in inflammatory bowel disease.
    Carty E; Nickols C; Feakins RM; Rampton DS
    J Clin Pathol; 2002 May; 55(5):367-70. PubMed ID: 11986343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility.
    Nie D; Che M; Zacharek A; Qiao Y; Li L; Li X; Lamberti M; Tang K; Cai Y; Guo Y; Grignon D; Honn KV
    Am J Pathol; 2004 Feb; 164(2):429-39. PubMed ID: 14742249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel pyridobenzazepinone derivative with long lasting thromboxane synthase inhibition.
    Miki I; Kishibayashi N; Takeda M; Suzuki K; Obase H; Ishii A
    Arzneimittelforschung; 1995 Oct; 45(10):1066-70. PubMed ID: 8595060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From the design to the clinical application of thromboxane modulators.
    Dogné JM; Hanson J; de Leval X; Pratico D; Pace-Asciak CR; Drion P; Pirotte B; Ruan KH
    Curr Pharm Des; 2006; 12(8):903-23. PubMed ID: 16533159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2.
    Sakai H; Suzuki T; Takahashi Y; Ukai M; Tauchi K; Fujii T; Horikawa N; Minamimura T; Tabuchi Y; Morii M; Tsukada K; Takeguchi N
    FEBS Lett; 2006 Jun; 580(14):3368-74. PubMed ID: 16709411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer.
    Cathcart MC; Gately K; Cummins R; Drakeford C; Kay EW; O'Byrne KJ; Pidgeon GP
    Biochim Biophys Acta; 2014 May; 1842(5):747-55. PubMed ID: 24480048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of thromboxane A2 inhibitors on allergic pulmonary inflammation in mice.
    Shi H; Yokoyama A; Kohno N; Hirasawa Y; Kondo K; Sakai K; Hiwada K
    Eur Respir J; 1998 Mar; 11(3):624-9. PubMed ID: 9596113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the thromboxane A2 synthetase inhibitor OKY-046 in a warm ischemia-reperfusion rat model.
    Garvin PJ; Niehoff ML; Robinson SM; Heisler T; Salinas-Madrigal L; Contis J; Solomon H
    Transplantation; 1996 May; 61(10):1429-34. PubMed ID: 8633364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective eicosanoid formation during HL-60 macrophage differentiation. Regulation of thromboxane synthase.
    Nüsing R; Goerig M; Habenicht AJ; Ullrich V
    Eur J Biochem; 1993 Mar; 212(2):371-6. PubMed ID: 8444174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro effects of E3040, a dual inhibitor of 5-lipoxygenase and thromboxane A(2) synthetase, on eicosanoid production.
    Oketani K; Nagakura N; Harada K; Inoue T
    Eur J Pharmacol; 2001 Jun; 422(1-3):209-16. PubMed ID: 11430933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.